Article
[Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Zhonghua yi xue za zhi - 15 Feb 2022
Xu H Y, Chen H Q, Kong J X, Zhang Y, Liu S, Yang G J, Wang Y
Abstract excerpt
Objective: To explore the prognosis of patients with leptomeningeal metastasis (LM) and epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) treated with different kinds of tyrosine kinase inhibitors (TKIs). Methods: From January 2016 to June 2021, the clinicopathological data of 70 patients confirmed by histologically or cytologically EGFRm LM who received different types of TKIs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.